|
RERE expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.85120000229367E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.3425999999539E-06 |
| Normal-vs-Stage2 |
1.817820E-03 |
| Normal-vs-Stage3 |
6.36650000496175E-08 |
| Normal-vs-Stage4 |
2.89519999974175E-07 |
| Stage1-vs-Stage2 |
7.261200E-01 |
| Stage1-vs-Stage3 |
1.370610E-01 |
| Stage1-vs-Stage4 |
1.356000E-01 |
| Stage2-vs-Stage3 |
1.960240E-01 |
| Stage2-vs-Stage4 |
1.611230E-01 |
| Stage3-vs-Stage4 |
7.325000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.93759999950794E-08 |
| Normal-vs-AfricanAmerican |
3.402100E-02 |
| Normal-vs-Asian |
3.91830000000537E-05 |
| Caucasian-vs-AfricanAmerican |
1.812390E-01 |
| Caucasian-vs-Asian |
8.079800E-01 |
| AfricanAmerican-vs-Asian |
2.382000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.31789999971532E-07 |
| Normal-vs-Female |
2.78390000052475E-07 |
| Male-vs-Female |
7.437400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.62549999963113E-07 |
| Normal-vs-Age(41-60Yrs) |
3.98940000000403E-05 |
| Normal-vs-Age(61-80Yrs) |
1.29170000029433E-07 |
| Normal-vs-Age(81-100Yrs) |
9.016500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.809200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.369400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.199800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.935580E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.044800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.513200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.88572999999526E-05 |
| Classical-VS-Follicular |
8.191800E-01 |
| Classical-VS-Other |
3.526000E-01 |
| Classical-VS-Normal |
2.15219999999405E-06 |
| Tall-VS-Follicular |
7.960000E-04 |
| Tall-VS-Other |
3.293800E-01 |
| Tall-VS-Normal |
1.51459955688438E-10 |
| Follicular-VS-Other |
4.697400E-01 |
| Follicular-VS-Normal |
2.407800E-04 |
| Other-VS-Normal |
1.012320E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.36069999999255E-05 |
| Normal-vs-N1 |
3.29179999924989E-08 |
| N0-vs-N1 |
3.274100E-02 |
|
|
